Skip to main content
bioRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search
New Results

Potent neutralization of 2019 novel coronavirus by recombinant ACE2-Ig

Changhai Lei, Wenyan Fu, Kewen Qian, Tian Li, Sheng Zhang, Min Ding, Shi Hu
doi: https://doi.org/10.1101/2020.02.01.929976
Changhai Lei
Second Military Medical University;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Wenyan Fu
Shanghai Jiao Tong University School of Medicine;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kewen Qian
Second Military Medical University;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Tian Li
Second Military Medical University;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sheng Zhang
Shanghai Jiao Tong University School of Medicine;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Min Ding
Pharchoice Therapeutics Inc;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Shi Hu
Second Militarily Medical University
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: hus@smmu.edu.cn
  • Abstract
  • Info/History
  • Metrics
  • Supplementary material
  • Preview PDF
Loading

Abstract

A novel coronavirus, designated as 2019-nCoV, emerged in Wuhan, China, at the end of 2019. As of Feb 1, 2020, at least 11,844 cases had been diagnosed in China, however, there is no specific antiviral treatment or vaccine currently. Very recently report have suggest that novel CoV uses the same cell entry receptor, ACE2, as SARS-CoV. In this report, we generated a new recombinant protein by connecting the extracellular domain of human ACE2 to the Fc region of the human immunoglobulin IgG1. An ACE2 mutant with low catalytic activity was also used in the study. The fusion proteins were then characterized. Both fusion proteins has high affinity binding to the receptor-binding domain (RBD) of SARS-CoV and 2019-nCoV and exerted desired pharmacological properties. Moreover, fusion proteins potently neutralized SARS-CoV and 2019-nCoV in vitro. As these fusion proteins exhibit cross-reactivity against coronavirus and could have potential applications for diagnosis, prophylaxis, and treatment of 2019-nCoV.

Copyright 
The copyright holder for this preprint is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Back to top
PreviousNext
Posted February 02, 2020.
Download PDF

Supplementary Material

Email

Thank you for your interest in spreading the word about bioRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Potent neutralization of 2019 novel coronavirus by recombinant ACE2-Ig
(Your Name) has forwarded a page to you from bioRxiv
(Your Name) thought you would like to see this page from the bioRxiv website.
Share
Potent neutralization of 2019 novel coronavirus by recombinant ACE2-Ig
Changhai Lei, Wenyan Fu, Kewen Qian, Tian Li, Sheng Zhang, Min Ding, Shi Hu
bioRxiv 2020.02.01.929976; doi: https://doi.org/10.1101/2020.02.01.929976
Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
Citation Tools
Potent neutralization of 2019 novel coronavirus by recombinant ACE2-Ig
Changhai Lei, Wenyan Fu, Kewen Qian, Tian Li, Sheng Zhang, Min Ding, Shi Hu
bioRxiv 2020.02.01.929976; doi: https://doi.org/10.1101/2020.02.01.929976

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Bioengineering
Subject Areas
All Articles
  • Animal Behavior and Cognition (1641)
  • Biochemistry (2721)
  • Bioengineering (1902)
  • Bioinformatics (10201)
  • Biophysics (4174)
  • Cancer Biology (3202)
  • Cell Biology (4522)
  • Clinical Trials (135)
  • Developmental Biology (2831)
  • Ecology (4447)
  • Epidemiology (2041)
  • Evolutionary Biology (7213)
  • Genetics (5463)
  • Genomics (6793)
  • Immunology (2379)
  • Microbiology (7462)
  • Molecular Biology (2978)
  • Neuroscience (18529)
  • Paleontology (135)
  • Pathology (472)
  • Pharmacology and Toxicology (776)
  • Physiology (1147)
  • Plant Biology (2692)
  • Scientific Communication and Education (679)
  • Synthetic Biology (885)
  • Systems Biology (2840)
  • Zoology (465)